Clinicopathological feature, observed at time of sample | |||
---|---|---|---|
Collection | Details | n | % of total |
Age at time of sample collection (y*) | Median | 59.50 | – |
IQR* | 20 | – | |
Range | 29-89 | – | |
Time spent in studya (m*) | Median | 23 | – |
IQR* | 27 | – | |
Range | 1-59 | – | |
Statusb | Alive | 101 | 52.1 |
Deceased | 93 | 47.9 | |
ER status | Positive | 157 | 80.9 |
Negative | 30 | 15.5 | |
Unknown | 7 | 3.6 | |
PR status | Positive | 115 | 59.3 |
Negative | 55 | 28.4 | |
Unknown | 24 | 12.4 | |
HER2 status | Positive | 35 | 18.0 |
Negative | 133 | 68.6 | |
Unknown | 26 | 13.4 | |
CTCs/7.5 ml blood, by CellSearch® | Median | 0.000 | – |
IQR* | 4.000 | – | |
Range | 0-6848 | – | |
0–4 | 148 | 76.3 | |
≥ 5 | 46 | 23.7 | |
cfDNA yield (ng/μl) | Median | 0.120 | – |
IQR* | 0.175 | – | |
Range | 0.003-5.460 | – | |
< 0.306 | 146 | 75.3 | |
≥ 0.306 | 48 | 24.7 | |
CA15-3 (U/ml) | Median | 49.000 | – |
IQR* | 149.250 | – | |
Range | 1-6313 | – | |
< 32 | 67 | 34.5 | |
≥ 32 | 127 | 65.5 | |
AP (IU/L) | Median | 89.500 | – |
IQR* | 46.750 | – | |
Range | 30-555 | – | |
< 130 | 154 | 79.4 | |
≥ 130 | 40 | 20.6 | |
Treatment patient undergoing at the time of blood sampling | Endocrine | 95 | 49.0 |
Chemotherapyc | 49 | 25.3 | |
HER2-targeted therapyd | 18 | 9.3 | |
Off treatment | 32 | 16.5 | |
Disease response at time of blood sampling | Responding | 30 | 15.5 |
Stable disease | 73 | 37.6 | |
Progressive disease | 91 | 46.9 |